J Bueno-de-Mesquita
J Bueno-de-Mesquita
Antes / Sprink
Verified email at sprink.nl
Title
Cited by
Cited by
Year
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ...
The lancet oncology 8 (12), 1079-1087, 2007
3042007
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
M Knauer, S Mook, EJT Rutgers, RA Bender, M Hauptmann, ...
Breast cancer research and treatment 120 (3), 655-661, 2010
2962010
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ...
International journal of cancer 133 (4), 929-936, 2013
2482013
Validation of 70-gene prognosis signature in node-negative breast cancer
JM Bueno-de-Mesquita, SC Linn, R Keijzer, J Wesseling, DSA Nuyten, ...
Breast cancer research and treatment 117 (3), 483-495, 2009
1952009
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer
P Roepman, HM Horlings, O Krijgsman, M Kok, JM Bueno-de-Mesquita, ...
Clinical Cancer Research 15 (22), 7003-7011, 2009
1052009
Technology Insight: tuning into the genetic orchestra using microarrays—limitations of DNA microarrays in clinical practice
A Abdullah-Sayani, JM Bueno-de-Mesquita, MJ Van De Vijver
Nature clinical practice Oncology 3 (9), 501-516, 2006
982006
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
S Mook, M Knauer, JM Bueno-de-Mesquita, VP Retel, J Wesseling, ...
Annals of surgical oncology 17 (5), 1406-1413, 2010
952010
Methodology of constructive technology assessment in health care
KFL Douma, K Karsenberg, MJM Hummel, JM Bueno-de-Mesquita, ...
International journal of technology assessment in health care 23 (2), 162-168, 2007
722007
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
JM Bueno-de-Mesquita, DSA Nuyten, J Wesseling, H van Tinteren, ...
Annals of oncology 21 (1), 40-47, 2010
622010
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
VP Retel, MA Joore, CA Drukker, JM Bueno-de-Mesquita, M Knauer, ...
European journal of cancer 49 (18), 3773-3779, 2013
332013
Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics
VP Retèl, JM Bueno-de-Mesquita, MJM Hummel, MJ van de Vijver, ...
International journal of technology assessment in health care 25 (1), 73-83, 2009
312009
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
CA Drukker, MV Nijenhuis, JM Bueno-de-Mesquita, VP Retèl, ...
Breast cancer research and treatment 145 (3), 697-705, 2014
292014
Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
JM Bueno-de-Mesquita, GS Sonke, MJ van de Vijver, SC Linn
Annals of oncology 22 (9), 2021-2030, 2011
282011
0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer
M Knauer, M Straver, E Rutgers, R Bender, F Cardoso, S Mook, ...
The Breast, S36-S37, 2009
112009
A new independent validation of the 70-gene signature in node-negative breast cancer
JMB de Mesquita, SC Linn, AAM Hart, C Van Krimpen, C Meijers, ...
EJC Supplements 2 (4), 131, 2006
72006
Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature.
M Knauer, F Cardoso, S Mook, P Bedard, R Koornstra, M Kok, ...
Cancer Research 69 (2 Supplement), 4171, 2009
52009
Use of a 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based study (RASTER)
JM de Mesquita, HWH Bueno, VP Retel
Lancet Oncol 8, 1079-1087, 2007
52007
10 years follow up of the RASTER study; implementing a genomic signature in daily practice
SB Vliek, V Retel, C Drukker, E Rutgers, H van Tinteren, MJ Van de Vijver, ...
Annals of oncology 28, v46, 2017
42017
Microarraybased readout of ER, PR, and HER2 expression in breast cancer tissue
P Roepman, HM Horlings, O Krijgsman, M Kok, R Koornstra, ...
ASCO Breast Cancer Symposium, 2008
42008
Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments
P Roepman, H Horlings, O Krijgsman, J Bueno-de-Mesquita, R Bender, ...
Lancet Oncol 8 (12), 1079-87, 2007
42007
The system can't perform the operation now. Try again later.
Articles 1–20